PMID- 29804272
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1523-3847 (Print)
IS  - 1523-3847 (Linking)
VI  - 20
IP  - 8
DP  - 2018 May 26
TI  - Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal 
      Microbiota Transplantation.
PG  - 21
LID - 10.1007/s11908-018-0627-8 [doi]
AB  - PURPOSE OF REVIEW: Fecal microbiota transplantation (FMT) has been investigated 
      as a potential treatment for inflammatory bowel disease (IBD). This review 
      examines current evidence around the efficacy and safety of FMT for patients with 
      IBD. RECENT FINDINGS: Randomized controlled trials (RCTs) and meta-analyses have 
      suggested that FMT may facilitate clinical and endoscopic remission in patients 
      with active ulcerative colitis (UC). Although the evidence for FMT in Crohn's 
      disease (CD) is more limited, positive outcomes have been observed in small 
      cohort studies. Most adverse events (AEs) were mild and included transient 
      gastrointestinal symptoms. Serious adverse events (SAEs) did not differ 
      significantly between the FMT and control groups, and a marginal increased rate 
      of IBD flares following FMT was observed. Microbiota analysis following FMT 
      showed increased intestinal bacterial diversity and a shift towards the donor 
      microbial profile in recipients' stools. FMT for patients with IBD is promising 
      as RCTs have shown the benefit of FMT for UC, although the efficacy of FMT for CD 
      is less clear. Further large and well-designed trials are necessary to resolve 
      critical issues such as the donor selection, the ideal route of administration, 
      duration, frequency of FMT, and the long-term sustained efficacy and safety.
FAU - Jeon, Seong Ran
AU  - Jeon SR
AD  - Digestive Disease Centre, Institute for Digestive Research, Soonchunhyang 
      University College of Medicine, Seoul, South Korea.
AD  - University of Victoria, Victoria, British Columbia, Canada.
FAU - Chai, Jocelyn
AU  - Chai J
AD  - University of British Columbia, Vancouver, Canada.
FAU - Kim, Christiana
AU  - Kim C
AD  - Vancouver Island Health Authority, Cumberland, Canada.
FAU - Lee, Christine H
AU  - Lee CH
AD  - University of Victoria, Victoria, British Columbia, Canada. 
      Christine.Lee@VIHA.CA.
AD  - University of British Columbia, Vancouver, Canada. Christine.Lee@VIHA.CA.
AD  - Vancouver Island Health Authority, Cumberland, Canada. Christine.Lee@VIHA.CA.
AD  - Department of Pathology and Molecular Medicine, McMaster University, St Joseph's 
      Healthcare, Hamilton, Ontario, Canada. Christine.Lee@VIHA.CA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180526
PL  - United States
TA  - Curr Infect Dis Rep
JT  - Current infectious disease reports
JID - 100888983
OTO - NOTNLM
OT  - Crohn's disease
OT  - Fecal microbiota transplantation
OT  - Inflammatory bowel disease
OT  - Ulcerative colitis
EDAT- 2018/05/29 06:00
MHDA- 2018/05/29 06:01
CRDT- 2018/05/28 06:00
PHST- 2018/05/28 06:00 [entrez]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2018/05/29 06:01 [medline]
AID - 10.1007/s11908-018-0627-8 [pii]
AID - 10.1007/s11908-018-0627-8 [doi]
PST - epublish
SO  - Curr Infect Dis Rep. 2018 May 26;20(8):21. doi: 10.1007/s11908-018-0627-8.